fedratinib (Inrebic)
Jump to navigation
Jump to search
Indications
- treatment of myeloproliferative diseases including myelofibrosis
Dosage
- 100 mg oral capsule
Monitor
Adverse effects
- common:
- iron-deficiency anemia, thrombocytopenia
- hepatotoxicity
- increased serum amylase or serum lipase
- boxed warning risk of serious & fatal encephalopathy, including Wernicke's encephalopathy
Mechanism of action
- semi-selective inhibitor of Janus kinase 2 (JAK2)
More general terms
References
- ↑ PubChem: 16722836
- ↑ Wikipedia: Fedratinib https://en.wikipedia.org/wiki/Fedratinib
- ↑ Pardanani A, Hood J, Lasho T et al TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007 Aug;21(8):1658-68. Epub 2007 May 31. PMID 17541402
- ↑ FDA News Release. Aug 16, 2919 FDA approves treatment for patients with rare bone marrow disorder. https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder